 |
77 Diseases |  |
4 Trials |
|
4 Trials |  |
151 News |  |
| «123» |
- | atomoxetine / Generic mfg.
Journal: Metabolic profiling of norepinephrine reuptake inhibitor atomoxetine. (Pubmed Central) - Jun 22, 2021
The findings concerning aldehydes should be very useful to further elucidate the mechanistic aspects of adverse effects associated with ATX from metabolic angles. Additionally, the species differences for each metabolite should be helpful to investigate the contribution of specific metabolites to ATX toxicity and possible drug-drug interactions in suitable models.
- | methoxyamine (TRC102) / Tracon Pharma
Journal: A noncovalent hybrid of [Pd(phen)(OAc)] and st-DNA for the enantioselective hydroamination of β-nitrostyrene with methoxyamine. (Pubmed Central) - May 25, 2021
We developed a novel Pd-catalysed enantioselective synthesis of C-N bonds using the chiral scaffold of DNA. The non-covalently linked [Pd(phen)(OAc)2] with st-DNA catalysed the Markonicov hydroamination of β-nitrostyrene with methoxyamine for the first time with >75% enantiomeric excess (ee) in an aqueous buffer (pH 7.4) at room temperature.
- | methoxyamine (TRC102) / Tracon Pharma
Journal: Characterization of Recombinant Endonuclease IV from Mycobacterium tuberculosis (Pubmed Central) - Apr 26, 2021
Enzymatic activity of MtbEnd was suppressed in the presence of methoxyamine, a chemotherapeutic agent that modifies AP sites. Based on the results, MtbEnd was assumed to provide a possible target for new anti-tuberculosis drugs.
- | methoxyamine (TRC102) / Tracon Pharma
Journal: Sample Multiplexing: Increased Throughput for Quantification of Total Testosterone in Serum by Liquid Chromatography-Tandem Mass Spectrometry. (Pubmed Central) - Mar 31, 2021
Based on the results, MtbEnd was assumed to provide a possible target for new anti-tuberculosis drugs. Sample multiplexing by differential mass tagging of TT increases LC-MS/MS throughput 2-fold without compromising analytical accuracy and sensitivity.
- pevonedistat (MLN4924) / Takeda, methoxyamine (TRC102) / Tracon Pharma
[VIRTUAL] Identifying signatures of vulnerability through machine learning in an umbrella trial for glioblastoma () - Mar 11, 2021 - Abstract #AACR2021AACR_2153;
Predicted vulnerability using genomic data from preclinical PDX models placed 4 out of 6 models into a “high likelihood of response” regimen. Our utilization of multiple vulnerability signatures in an umbrella trial demonstrates how a precision medicine model can support an efficient clinical trial for heterogeneous diseases such as GBM.
- | methoxyamine (TRC102) / Tracon Pharma
Trial completion date, Trial primary completion date: Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin (clinicaltrials.gov) - Jan 20, 2021
P2, N=58, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Our utilization of multiple vulnerability signatures in an umbrella trial demonstrates how a precision medicine model can support an efficient clinical trial for heterogeneous diseases such as GBM. Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021
- || methoxyamine (TRC102) / Tracon Pharma
Clinical, P1 data, Journal, Combination therapy: Phase I trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed solid tumors and lymphomas. (Pubmed Central) - Nov 22, 2020
Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021 The combination of TRC 102 with temozolomide is active, with 4 of 51 patients experiencing a partial response and 13 of 51 experiencing stable disease, and the side effect profile is manageable.
- | methoxyamine (TRC102) / Tracon Pharma
Trial completion date, Trial primary completion date: TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas (clinicaltrials.gov) - Jul 9, 2020
P1/2, N=140, Recruiting, Sponsor: National Cancer Institute (NCI)
The combination of TRC 102 with temozolomide is active, with 4 of 51 patients experiencing a partial response and 13 of 51 experiencing stable disease, and the side effect profile is manageable. Trial completion date: Feb 2021 --> Feb 2022 | Trial primary completion date: Dec 2020 --> Feb 2022
- [VIRTUAL] Phase I study of TRC102 in combination with cisplatin and pemetrexed in patients with advanced solid tumors/Phase II study of TRC102 with pemetrexed in patients with mesothelioma refractory to pemetrexed and cisplatin or carboplatin. (Poster Board 248) - Apr 29, 2020 - Abstract #ASCO2020ASCO_2324;
P2
The combination of TRC102 and pemetrexed demonstrated activity in malignant mesothelioma that progressed on prior pemetrexed. Additional studies are warranted to confirm preliminary signals of activity.
- methoxyamine (TRC102) / Tracon, pemetrexed / Generic mfg.
[VIRTUAL] Base excision repair (BER) inhibitor TRC 102 (Methoxyamine) combined with pemetrexed (PEM)-based chemo-radiation (CRT) for locally advanced non-squamous non-small cell lung cancer (NS-NSCLC): Results of a phase I trial. (Poster Board 220) - Apr 29, 2020 - Abstract #ASCO2020ASCO_2298;
P1
Preliminary response data and PFS in this cohort was encouraging. A phase 2 trial, integrating post-CRT immunotherapy with this aggressive DNA-damaging regimen is warranted.
- | methoxyamine (TRC102) / Tracon Pharma
Trial primary completion date: Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin (clinicaltrials.gov) - Apr 10, 2020
P2, N=58, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
A phase 2 trial, integrating post-CRT immunotherapy with this aggressive DNA-damaging regimen is warranted. Trial primary completion date: Jun 2020 --> Dec 2020
- | methoxyamine (TRC102) / Tracon Pharma
Enrollment closed, Trial primary completion date: Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin (clinicaltrials.gov) - Nov 18, 2019
P2, N=58, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jun 2020 --> Dec 2020 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2019 --> Jun 2020
- methoxyamine (TRC102) / Tracon, temozolomide / Generic Mfg., Avastin (bevacizumab) / Roche
Genomic analysis of responders of phase II trial of temozolomide and TRC-102 (base excision repair inhibitor) in bevacizumab-naïve glioblastoma at first recurrence (Ballroom Lawn) - Oct 29, 2019 - Abstract #SNO2019SNO_944;
TRC 102 with temozolomide has acceptable safety but did not meet the primary endpoint of response. Gene signature of MsigDB, CIN70, CIN25 and PCNA25 was seen in exceptional responders and biomarker driven study is planned.
- | methoxyamine (TRC102) / Tracon Pharma
Trial primary completion date: Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer (clinicaltrials.gov) - Oct 8, 2019
P1, N=15, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Gene signature of MsigDB, CIN70, CIN25 and PCNA25 was seen in exceptional responders and biomarker driven study is planned. Trial primary completion date: Sep 2019 --> Jan 2021
- | methoxyamine (TRC102) / Tracon Pharma
Enrollment closed: Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer (clinicaltrials.gov) - Jul 30, 2019
P1, N=15, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Sep 2019 --> Jan 2021 Recruiting --> Active, not recruiting
- | methoxyamine (TRC102) / Tracon Pharma
Trial completion date, Trial primary completion date: TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas (clinicaltrials.gov) - Jul 18, 2019
P1/2, N=140, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Trial completion date: Feb 2020 --> Dec 2020 | Trial primary completion date: Dec 2019 --> Dec 2020
- | methoxyamine (TRC102) / Tracon Pharma
Enrollment change: Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin (clinicaltrials.gov) - Apr 12, 2019
P2, N=58, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Feb 2020 --> Dec 2020 | Trial primary completion date: Dec 2019 --> Dec 2020 N=33 --> 58
- | methoxyamine (TRC102) / Tracon Pharma
Trial termination: Methoxyamine and Temozolomide in Treating Patients With Recurrent Glioblastoma (clinicaltrials.gov) - Apr 4, 2019
P2, N=20, Terminated, Sponsor: National Cancer Institute (NCI)
N=33 --> 58 Active, not recruiting --> Terminated; Pre-specified response criteria not met to proceed to next stage of study.
- | methoxyamine (TRC102) / Tracon Pharma
Enrollment change, Trial primary completion date: Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin (clinicaltrials.gov) - Feb 15, 2019
P2, N=33, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Terminated; Pre-specified response criteria not met to proceed to next stage of study. N=58 --> 33 | Trial primary completion date: Jun 2020 --> Dec 2019
- | methoxyamine (TRC102) / Tracon Pharma
Trial primary completion date: Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin (clinicaltrials.gov) - Dec 10, 2018
P2, N=58, Recruiting, Sponsor: National Cancer Institute (NCI)
N=58 --> 33 | Trial primary completion date: Jun 2020 --> Dec 2019 Trial primary completion date: Dec 2018 --> Jun 2020
- | methoxyamine (TRC102) / Tracon Pharma
Trial primary completion date: Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer (clinicaltrials.gov) - Nov 26, 2018
P1, N=15, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2018 --> Jun 2020 Trial primary completion date: Oct 2018 --> Sep 2019
- | methoxyamine (TRC102) / Tracon Pharma
Enrollment change: Methoxyamine and Temozolomide in Treating Patients With Recurrent Glioblastoma (clinicaltrials.gov) - May 30, 2018
P2, N=19, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Oct 2018 --> Sep 2019 N=66 --> 19
- | methoxyamine (TRC102) / Tracon Pharma
Enrollment change: TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas (clinicaltrials.gov) - Apr 27, 2018
P1/2, N=140, Recruiting, Sponsor: National Cancer Institute (NCI)
N=66 --> 19 N=65 --> 140
- | methoxyamine (TRC102) / Tracon Pharma
Trial primary completion date: Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin (clinicaltrials.gov) - Oct 12, 2017
P2, N=58, Recruiting, Sponsor: National Cancer Institute (NCI)
N=65 --> 140 Trial primary completion date: Aug 2017 --> Dec 2018
- | methoxyamine (TRC102) / Tracon Pharma
Trial primary completion date: Methoxyamine and Temozolomide in Treating Patients With Recurrent Glioblastoma (clinicaltrials.gov) - Aug 18, 2017
P2, N=66, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Aug 2017 --> Dec 2018 Trial primary completion date: Aug 2017 --> Mar 2018
- | methoxyamine (TRC102) / Tracon Pharma
Trial completion: Methoxyamine and Temozolomide in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jul 28, 2017
P1, N=66, Completed, Sponsor: Case Comprehensive Cancer Center
Trial primary completion date: Aug 2017 --> Mar 2018 Active, not recruiting --> Completed
- | methoxyamine (TRC102) / Tracon Pharma
Phase classification: TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas (clinicaltrials.gov) - Jul 26, 2017
P1/2, N=65, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Phase classification: P1 --> P1/2
- | methoxyamine (TRC102) / Tracon Pharma
Enrollment open: Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer (clinicaltrials.gov) - Apr 19, 2017
P1, N=15, Recruiting, Sponsor: National Cancer Institute (NCI)
Phase classification: P1 --> P1/2 Suspended --> Recruiting
- | methoxyamine (TRC102) / Tracon Pharma
Enrollment closed, Trial primary completion date: Methoxyamine and Temozolomide in Treating Patients With Recurrent Glioblastoma (clinicaltrials.gov) - Mar 21, 2017
P2, N=66, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Suspended --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2017 --> Aug 2017
- | methoxyamine (TRC102) / Tracon Pharma
Trial suspension: Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer (clinicaltrials.gov) - Mar 6, 2017
P1, N=15, Suspended, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2017 --> Aug 2017 Recruiting --> Suspended
- methoxyamine (TRC102) / Tracon Pharma
Trial primary completion date: Methoxyamine and Temozolomide in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Sep 30, 2016
P1, N=67, Recruiting, Sponsor: Case Comprehensive Cancer Center
Recruiting --> Suspended Trial primary completion date: Oct 2016 --> Apr 2017
- methoxyamine (TRC102) / Tracon Pharma
Trial primary completion date: TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas (clinicaltrials.gov) - Sep 7, 2016
P1, N=65, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Oct 2016 --> Apr 2017 Trial primary completion date: Jan 2017 --> Dec 2019
- methoxyamine (TRC102) / Tracon Pharma
Phase classification: Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin (clinicaltrials.gov) - Jul 1, 2016
P2, N=58, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jan 2017 --> Dec 2019 Phase classification: P1/2 --> P2
- methoxyamine (TRC102) / Tracon Pharma
Enrollment open, Trial primary completion date: Methoxyamine and Temozolomide in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Apr 22, 2016
P1, N=67, Recruiting, Sponsor: Case Comprehensive Cancer Center
Phase classification: P1/2 --> P2 Active, not recruiting --> Recruiting | Trial primary completion date: Apr 2016 --> Oct 2016
- methoxyamine (TRC102) / Tracon Pharma
Enrollment closed: Methoxyamine and Temozolomide in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Feb 21, 2016
P1, N=66, Active, not recruiting, Sponsor: Case Comprehensive Cancer Center
Active, not recruiting --> Recruiting | Trial primary completion date: Apr 2016 --> Oct 2016 Recruiting --> Active, not recruiting
- methoxyamine (TRC102) / Tracon Pharma
Phase classification: Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin (clinicaltrials.gov) - Feb 16, 2016
P1/2, N=58, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Phase classification: P1 --> P1/2
- methoxyamine (TRC102) / Tracon Pharma
Trial primary completion date: TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas (clinicaltrials.gov) - Feb 8, 2016
P1, N=55, Recruiting, Sponsor: National Cancer Institute (NCI)
Phase classification: P1 --> P1/2 Trial primary completion date: Jan 2016 --> Jan 2017
- methoxyamine (TRC102) / Tracon Pharma
Enrollment open: Methoxyamine and Temozolomide in Treating Patients With Recurrent Glioblastoma (clinicaltrials.gov) - Dec 29, 2015
P2, N=66, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jan 2016 --> Jan 2017 Not yet recruiting --> Recruiting
- methoxyamine (TRC102) / Tracon Pharma
Enrollment change: Methoxyamine and Temozolomide in Treating Patients With Recurrent Glioblastoma (clinicaltrials.gov) - Dec 21, 2015
P2, N=66, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting N=51 --> 66
- methoxyamine (TRC102) / Tracon Pharma
Trial primary completion date: Methoxyamine and Temozolomide in Treating Patients With Recurrent Glioblastoma (clinicaltrials.gov) - Nov 24, 2015
P2, N=51, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
N=51 --> 66 Trial primary completion date: Feb 2016 --> Jan 2017
- methoxyamine (TRC102) / Tracon Pharma
Enrollment open, Trial primary completion date: Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer (clinicaltrials.gov) - Nov 6, 2015
P1, N=15, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Feb 2016 --> Jan 2017 Not yet recruiting --> Recruiting | Trial primary completion date: Feb 2018 --> Oct 2018
- methoxyamine (TRC102) / Tracon Pharma
Trial primary completion date: Methoxyamine and Temozolomide in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Oct 23, 2015
P1, N=78, Recruiting, Sponsor: Case Comprehensive Cancer Center
Not yet recruiting --> Recruiting | Trial primary completion date: Feb 2018 --> Oct 2018 Trial primary completion date: Oct 2015 --> Apr 2016
- methoxyamine (TRC102) / Tracon Pharma
Trial initiation date: Methoxyamine and Temozolomide in Treating Patients With Recurrent Glioblastoma (clinicaltrials.gov) - Oct 22, 2015
P2, N=51, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Oct 2015 --> Apr 2016 Initiation date: Jun 2015 --> Dec 2015
- methoxyamine (TRC102) / Tracon Pharma
Enrollment open: Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin (clinicaltrials.gov) - Oct 22, 2015
P1, N=58, Recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Jun 2015 --> Dec 2015 Suspended --> Recruiting
- methoxyamine (TRC102) / Tracon Pharma
Enrollment change: TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas (clinicaltrials.gov) - Oct 1, 2015
P1, N=55, Recruiting, Sponsor: National Cancer Institute (NCI)
Suspended --> Recruiting N=40 --> 55
- methoxyamine (TRC102) / Tracon Pharma
New P1 trial: Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin (clinicaltrials.gov) - Aug 28, 2015
P1, N=58, Suspended, Sponsor: National Cancer Institute (NCI)
- methoxyamine (TRC102) / Tracon Pharma
New P1 trial: Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer (clinicaltrials.gov) - Aug 28, 2015
P1, N=15, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- methoxyamine (TRC102) / Tracon Pharma
Trial completion: Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies (clinicaltrials.gov) - Aug 14, 2015
P1, N=20, Completed, Sponsor: Case Comprehensive Cancer Center
N=40 --> 55 Active, not recruiting --> Completed
- methoxyamine (TRC102) / Tracon Pharma
Enrollment change: Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies (clinicaltrials.gov) - Apr 25, 2015
P1, N=20, Active, not recruiting, Sponsor: Case Comprehensive Cancer Center
Active, not recruiting --> Completed N=30 --> 20
- methoxyamine (TRC102) / Tracon Pharma
Enrollment change, Trial primary completion date: Methoxyamine and Temozolomide in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Apr 25, 2015
P1, N=78, Recruiting, Sponsor: Case Comprehensive Cancer Center
N=30 --> 20 N=42 --> 78 | Trial primary completion date: Apr 2015 --> Oct 2015